Stage III colorectal cancer
Conditions
Interventions
Standard Arm(Daily administrations) TS-1 is administered orally for 28 days, followed by 14 days rest. Administrations are conducted for 24 weeks from the date of the start of the therapy. After the
Sponsors
Clinical Study Group of Osaka (CSGO), Colorectal Cancer Treatment Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically proven, Stage III, (Japanese Classification of Colorectal cancer 8th Edition) primary Colon cancer or RS. 2)Curability A 3)Age between 20 and 80 years. 4)Performance status(ECOG) of 0-1. 5)No prior therapy expect the operation. 6)Capability of oral intake 7)Patients who have satisfied the clinical test values within 14 days before the registration. 8)Patient with starting the treatment within 8 weeks after operation. 9)Written informed consent.
Exclusion criteria
Exclusion criteria: 1)Active double cancer 2)Synchronous or metachronous malignancy other than carcinoma in situ. 3)Severe postoperative complications. 4)Severe complication. 5)Severe diarrhea. 6)Severe infectious disease. 7)Medical history of severe anaphylaxis or allergia to any drug. 8)Undergoing treatment with fluorocytosine. 9)Hepatitis B virus infection, hepatitis C virus infection. 10)Women who are pregnant or breast-feeding, or Women who may become pregnant and fertile men. 11)Severe mental disorder. 12)Patients judged inappropriate for the study by their physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment Completion Rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year Disease-Free Survival Overall Survival Compliance Safety | — |
Countries
Japan
Contacts
Public ContactTaishi Hata
Osaka University Graduate School of Medicine Gastroenterological Surgery
Outcome results
None listed